TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
This study is testing a new combination of drugs for people with a specific type of advanced lung cancer. Researchers want to see if adding an immunotherapy drug, which helps the body's immune system fight cancer, to standard chemotherapy and targeted treatments can lead to better outcomes for patients.
This trial is for people with stage 4 non-small cell lung cancer who are either 'never-smokers' or have a specific genetic change called an EGFR mutation. Participants must meet certain health requirements, such as having stable heart health and no recent serious internal bleeding.
Participants will receive a combination of chemotherapy and drug treatments to help fight their cancer. The medical team will closely monitor you with regular scans and check-ups to track how well the treatment is working and how you are feeling.
This study is located in Philadelphia, Pennsylvania. The trial is currently active but is no longer looking for new volunteers.
- 1The study explores a treatment approach that combines chemotherapy, targeted therapy, and immunotherapy.
- 2It focuses specifically on lung cancer patients who have never smoked or have a specific EGFR mutation.
- 3Participation involves regular monitoring by a medical team to ensure safety and track the cancer's response.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.